Targeted therapies for cancer ?from tamoxifen to gefitinib (¡®Iressa?

详细信息    查看全文

• 作者：Jeffrey H. Hanke¹ ; ^{jeff.hanke@astrazeneca.com} ; Les R. Hughes²
• 刊名：Drug Discovery Today: Therapeutic Strategies
• 出版年：2004
• 出版时间：December 2004
• 年：2004
• 卷：1
• 期：4
• 页码：411-416
• 全文大小：129 K

文摘

| ReferencesReferences

Section Editors:

Lance Liotta ?National Institutes of Health, Bethesda, MD, USA

Neil Gibson ?OSI Pharmaceuticals, NY, USA

The dawn of molecular-targeted therapy in Oncology first started with the discovery of antagonists of the estrogen receptor in the 1960s. It is only recently that additional progress has been made with the discovery and development of EGF/EGFR inhibitors, inhibitors of bcr/abl and the c-kit kinase, although one could argue that TS inhibitors and topoisomerase inhibitors are also examples of targeted therapies. In this article, Hanke and Hughes discuss what lessons can be learned from the development of tamoxifen and relates how they can be applied to the current wave of targeted therapies. This is crucial if we are to fulfill the promise of this new treatment paradigm and the authors present a strong and compelling argument that provides hope for the future.